Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak

Plus: J&J Finds Manufacturing Partner, AZ To Investigate Heart Complications

The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.

Vials_Remdesivir
Three Phase III readouts are expected in the next few weeks, which should provide a clearer picture on remdesivir

Data from a trial in China of Gilead Sciences Inc.’s antiviral treatment remdesivir have been posted by accident online by the World Health Organization, showing that the treatment did not improve the condition of patients with severe COVID-19 or reduce the presence of the virus in the bloodstream.

The study also found the remdesivir arm produced more discontinuations due to adverse events, raising safety concerns.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By 

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.